[{"id":"50b1d2ff-2ef3-453b-9f2f-2564d9c8d558","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616196","created_at":"2021-01-19T20:33:33.968Z","updated_at":"2024-07-02T16:35:04.204Z","phase":"Phase 1/2","brief_title":"Study of NKTR 255 in Combination With Cetuximab in Solid Tumors","source_id_and_acronym":"NCT04616196","lead_sponsor":"Nektar Therapeutics","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • avipendekin pegol (NKTR-255)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2024-05-13"},{"id":"b244d21b-7ca6-459d-808a-603983ee64ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03233854","created_at":"2021-01-18T15:58:49.473Z","updated_at":"2024-07-02T16:35:17.505Z","phase":"Phase 1","brief_title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT03233854","lead_sponsor":"Crystal Mackall, MD","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 positive • CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-02-28"},{"id":"453e9d9e-7fd2-4c50-9add-8dcae3118995","acronym":"NCI-2022-02316","url":"https://clinicaltrials.gov/study/NCT05359211","created_at":"2022-05-03T14:54:08.402Z","updated_at":"2024-07-02T16:35:20.758Z","phase":"Phase 1","brief_title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT05359211 - NCI-2022-02316","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • avipendekin pegol (NKTR-255)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/08/2022","start_date":" 12/08/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-06"},{"id":"5992e1f2-63b6-45f1-8c22-41240b0aaf81","acronym":"","url":"https://clinicaltrials.gov/study/NCT03995472","created_at":"2022-07-14T16:59:43.900Z","updated_at":"2024-07-02T16:35:35.528Z","phase":"Phase 1","brief_title":"A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors","source_id_and_acronym":"NCT03995472","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiLi (adebrelimab) • SHR-1501"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 01/12/2023","primary_completion_date":" 01/12/2023","study_txt":" Completion: 01/12/2023","study_completion_date":" 01/12/2023","last_update_posted":"2023-09-27"}]